Passage Bio Stock Performance
| PASG Stock | USD 0.33 0.04 10.81% |
The company holds a Beta of 2.31, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. At this point, Passage Bio has a negative expected return of -0.81%. Please make sure to check Passage Bio's kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Passage Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Passage Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in May 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
1 | Acquisition by Sondhi Dolan of 48000 shares of Passage Bio at 0.848 subject to Rule 16b-3 | 01/24/2025 |
2 | Acquisition by Sondhi Dolan of 092 shares of Passage Bio at 1.28 subject to Rule 16b-3 | 01/31/2025 |
3 | Acquisition by Chou William of 575000 shares of Passage Bio at 1.5 subject to Rule 16b-3 | 02/06/2025 |
4 | Disposition of 12500 shares by Fotopoulos Alexandros of Passage Bio subject to Rule 16b-3 | 02/07/2025 |
5 | Disposition of 8000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3 | 02/10/2025 |
6 | Disposition of 3183 shares by Kathleen Borthwick of Passage Bio at 0.5296 subject to Rule 16b-3 | 02/11/2025 |
7 | Genetic Medicine Pioneer Passage Bio Sets March Investor Conference Schedule - StockTitan | 02/26/2025 |
8 | Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights | 03/04/2025 |
9 | Acquisition by Cale Edgar B. of 50000 shares of Passage Bio subject to Rule 16b-3 | 03/07/2025 |
10 | Passage Bio stock plunges to 52-week low of 0.38 amid market challenges - Investing.com India | 03/13/2025 |
11 | Acquisition by Cale Edgar B. of 278386 shares of Passage Bio at 0.387 subject to Rule 16b-3 | 03/14/2025 |
12 | Disposition of 75007 shares by Orbimed Advisors Llc of Passage Bio at 0.68 subject to Rule 16b-3 | 03/19/2025 |
13 | Passage Bio stock plunges to 52-week low of 0.35 - Investing.com | 03/31/2025 |
14 | Disposition of 10326 shares by Orbimed Advisors Llc of Passage Bio at 0.38 subject to Rule 16b-3 | 04/15/2025 |
15 | Disposition of 61638 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3 | 04/16/2025 |
16 | Disposition of 77090 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3 | 04/17/2025 |
| Begin Period Cash Flow | 21.7 M |
Passage Bio Relative Risk vs. Return Landscape
If you would invest 62.00 in Passage Bio on January 20, 2025 and sell it today you would lose (29.00) from holding Passage Bio or give up 46.77% of portfolio value over 90 days. Passage Bio is currently does not generate positive expected returns and assumes 6.1649% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Passage, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Passage Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Passage Bio, and traders can use it to determine the average amount a Passage Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1322
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PASG |
Estimated Market Risk
| 6.16 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.81 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Passage Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Passage Bio by adding Passage Bio to a well-diversified portfolio.
Passage Bio Fundamentals Growth
Passage Stock prices reflect investors' perceptions of the future prospects and financial health of Passage Bio, and Passage Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Passage Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | (30.77 M) | ||||
| Shares Outstanding | 62.15 M | ||||
| Price To Book | 0.33 X | ||||
| EBITDA | (70.4 M) | ||||
| Net Income | (64.77 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 25.48 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 0.99 X | ||||
| Cash Flow From Operations | (47.96 M) | ||||
| Earnings Per Share | (1.07) X | ||||
| Market Capitalization | 20.51 M | ||||
| Total Asset | 102.41 M | ||||
| Retained Earnings | (659.24 M) | ||||
| Working Capital | 59.45 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
About Passage Bio Performance
By analyzing Passage Bio's fundamental ratios, stakeholders can gain valuable insights into Passage Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Passage Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Passage Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.85) | (0.89) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (1.06) | (1.00) |
Things to note about Passage Bio performance evaluation
Checking the ongoing alerts about Passage Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Passage Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Passage Bio generated a negative expected return over the last 90 days | |
| Passage Bio has high historical volatility and very poor performance | |
| Passage Bio has some characteristics of a very speculative penny stock | |
| Passage Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Passage Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 77090 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3 |
- Analyzing Passage Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Passage Bio's stock is overvalued or undervalued compared to its peers.
- Examining Passage Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Passage Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Passage Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Passage Bio's stock. These opinions can provide insight into Passage Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |